Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Paulson Grows Bullish on American Capital $ACAS

On December 22, 2011, John Paulson reduced his stake in American Capital, Ltd (ACAS) by 6.15%, bringing his total shares in the company to just under 32.85 million. The decrease is only Paulson’s latest with regard to ACAS.

John Paulson’s Paulson & Co. had initiated a 43,725,000 share position in the company in the second quarter of 2010, when the average share price in ACAS was $5.47. In the third quarter, when ACAS’s average share price was $8.84 a share, Paulson unloaded 4,914,141 shares in the company. The sale brought his total shares to 38,810,859 at the end of September. PAULSON & CO

Since then, Paulson has been selling off shares in ACAS periodically. He sold more than 10% of his stake in the company on October 4, 2011, then by just over 3%the next day, which brought his shares in ACAS down to 36,279,900. Paulson held that position until October 11, when he sold another 3.53% of his position to bring his total holding in the company to 35,000,000 shares. Now, he is cutting his stake in ACAS once again. Paulson sold off 6.15% of his stake in the company on December 22, bringing his position to 32,846,800 shares (see the complete SEC filing here). The average sale price was $7.15-$7.16 a share.

ACAS  opened trading today at $7.01 a share. It is currently priced at 3.37 times its earnings. Analysts predict give the stock a one-year target estimate of $10-11, and recommend the stock as a sell, rating it 2.2 on a scale in which 1.0 means strong buy and 5.0 means sell. Analysts also predict the company’s earnings will outperform its industry over the next five years, growing by 15% per annum compared to industry expectations of 12.06% per annum. It doesn’t sound bad, but scratch the surface. ACAS’s third quarter net income was $464 million in the red, compared to $410 million at the end of the second quarter.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!